Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 7, 2025, MetaVia Inc. (MTVA) announced financial results for the second quarter of 2025 and provided a business update.</li><li>The company recently announced the extension of the 48 mg cohort from the Phase 1 trial of DA-1726, a dual GLP1/GCGR agonist, to 8-weeks in order to evaluate longer-term early efficacy and safety.</li><li>We anticipate results from this cohort before the end of 2025.</li></ul>

On August 7, 2025, MetaVia Inc. (MTVA) announced financial results for the second quarter of 2025 and provided a business update.The company recently announced the extension of the 48 mg cohort from the Phase 1 trial of DA-1726, a dual GLP1/GCGR agonist, to 8-weeks in order to evaluate longer-term early efficacy and safety.We anticipate results from this cohort before the end of 2025.

MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025 